相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
Kunio Sugahara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects
Tomohiko Harada et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2016)
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence
Bhupendra O. Khatri
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Clinical Characteristics and Circumstances of Death in the Sudden Arrhythmic Death Syndrome
Greg Mellor et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2014)
Oral fingolimod (FTY720) in multiple sclerosis Two-year results of a phase II extension study
P. O'Connor et al.
NEUROLOGY (2009)
分享论文
